The models of TP53 loss in head and neck, skin, breast, and the biliary gland performed well (PR-AUC-E above 0.2) in the other data set, suggesting that the predictive performance generalises independent of metastatic tumour state (Figure 3—figure supplement 1; Supplementary file 1h). The gene discussed is TP53; the disease is neoplasm.